Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

source https://finance.yahoo.com/news/synlogic-discontinues-development-synb1020-stock-220310930.html?.tsrc=rss